UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35986 Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 26-1870780 (State or other jurisdiction o ...

Esperion Therapeutics, Inc. (ESPR) incurred a loss of 5 cents per share for the second quarter of 2024, which was narrower than the Zacks Consensus Estimate of a loss of 15 cents. The company had incurred a loss of 46 cents per share in the year-ago quarter. Esperion generated revenues of $73.8 million, up nearly 186% year over year, driven by higher collaboration revenues and product revenues in the United States. The reported figure beat the Zacks Consensus Estimate of $52 million. Quarter in Detail Esper ...

ESPERION REACHING GOALS Q2 2024 Earnings Presentation August 12, 2024 Forward-looking Statements & Disclosures This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization plans, current and planned operational expenses, future operations, commercial products, clinical development, including the timing, designs and plans for the CLEAR Outcomes study and its r ...

Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.46 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 66.67%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.08 per share when it actually produced earnings of $0.34, delivering a surprise of 525%. Over the last four quarters ...

Exhibit 99.1 Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update – Total Revenue Increased 186% Year-over-Year to $73.8 Million with U.S. Net Product Revenue of $28.3 Million, Representing 39% Growth – – Total Retail Prescription Equivalents Increased 14% from First Quarter, with ~11% Increase During Final Four Weeks of Second Quarter – – Completed Transformational Transaction by Monetizing European Royalties on Bempedoic Acid Product Sales to OMERS Life Sciences for $304.7 ...

– Total Revenue Increased 186% Year-over-Year to $73.8 Million with U.S. Net Product Revenue of $28.3 Million, Representing 39% Growth – – Total Retail Prescription Equivalents Increased 14% from First Quarter, with ~11% Increase During Final Four Weeks of Second Quarter – – Completed Transformational Transaction by Monetizing European Royalties on Bempedoic Acid Product Sales to OMERS Life Sciences for $304.7 Million and Allocated Proceeds for Early, Discounted Payoff and Termination of Oberland Capital Re ...

ANN ARBOR, Mich., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on August 7, 2024, the Company granted 18 new employees 66,800 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to suc ...

– Animated Characters Are a Visual Representation of An Unseen Risk "Lurking" In Patients' Artery Walls – "The Lipid Lurkers campaign was developed as a visual way to bring high LDL cholesterol to life and help patients understand and become better educated on the havoc that too much bad cholesterol is causing inside their artery walls," according to Eric Warren, R.Ph., Chief Commercial Officer, Esperion. "Of the multiple concepts tested, the Lipid Lurkers campaign was rated best among patients with high LD ...

J. Wood Capital Advisors served as the financial advisor to the company on the royalty sale transaction. – Esperion Retains Rights to Receive all Potential Future Milestones of up to $300 Million Based on Commercial Performance from its Exclusive European Licensee, Daiichi Sankyo Europe – Under the terms of the Agreement, OMERS will receive this tiered royalty, which ranges from 15-25% of net bempedoic acid product sales in Europe, until it has received an aggregate amount equal to 1.7x investment. Thereaft ...

It has been about a month since the last earnings report for Esperion Therapeutics (ESPR) . Shares have added about 14.2% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Esperion Therapeutics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Esperion Q1 Earnings an ...